MPR Weekly Dose 88 - Postexposure Tx for COVID-19; Novel lupus treatment; Higher dose naloxone; Clozapine REMS changes; Istodax indication withdrawn

The FDA authorizes a postexposure prophylaxis for COVID-19; a new treatment is okay'd for lupus; a higher dose naloxone nasal spray became available; the risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.

Episode metadata supplied by the publisher feed · Published Aug 6, 2021

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose 88 - Postexposure Tx for COVID-19; Novel lupus treatment; Higher dose naloxone; Clozapine REMS changes; Istodax indication withdrawn

0:00 10:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 10 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on August 6, 2021.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!